Table 1.
Characteristics of the included studies in the meta-analysis
| No. | Authors and year of publication | Country | Patients (n) | Treatment group | Control group | |||
| Treatment | Control | Pre-op | Post-op | Pre-op | Post-op | |||
| 1 | Schuhmacher et al[15], 2010 | Germany | 72 | 72 | 5-FU + DDP | None | None | None |
| 2 | Boige et al[11], 2011 | France | 113 | 111 | FP | FP | None | None |
| 3 | Cunningham et al[12], 2006 | United Kingdom | 250 | 253 | ECF | ECF | None | None |
| 4 | Hartgrink et al[13], 2004 | Holland | 27 | 29 | FAMTX | None | None | |
| 5 | Zhang et al[17], 2004 | China | 37 | 54 | IV (no details) | None | None | |
| 6 | Kobayashi et al[14], 2000 | Japan | 91 | 80 | 5-FU (oral) | CT | None | None |
| 7 | Wang et al[16], 2000 | China | 30 | 30 | 5-FU (oral) | None | None | |
5-FU: 5-fluorouracil; DDP: Cisplatin; FP: 5-FU/cisplatin; ECF: Epirubicin/cyclophosphamide/5-FU; FAMTX: 5-FU/adriamycin/methotrexate; CT: Chemotherapy; IV: Intravenous; Pre-op: Preoperative; Post-op: Postoperative.